Basit öğe kaydını göster

dc.contributor.authorSever, Mehmet Sukru
dc.contributor.authorOztop, Nida
dc.contributor.authorCelik, Dilara
dc.contributor.authorYazici, Halil
dc.contributor.authorOzluk, Yasemin
dc.contributor.authorKilicaslan, Isin
dc.contributor.authorCaliskan, Yasar
dc.contributor.authorAksoy, Aysun
dc.contributor.authorUcar, Ayse Serra
dc.date.accessioned2021-03-04T12:39:20Z
dc.date.available2021-03-04T12:39:20Z
dc.date.issued2016
dc.identifier.citationCaliskan Y., Ozluk Y., Celik D., Oztop N., Aksoy A., Ucar A. S. , Yazici H., Kilicaslan I., Sever M. S. , "The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy", KIDNEY & BLOOD PRESSURE RESEARCH, cilt.41, sa.2, ss.148-157, 2016
dc.identifier.issn1420-4096
dc.identifier.otherav_78594ff3-1f09-43ec-8b98-5ca67672413d
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/82573
dc.identifier.urihttps://doi.org/10.1159/000443415
dc.description.abstractBackground/Aims: The aim of this study is to investigate the utility of clinical [age, gender, mean arterial pressure (MAP)] and laboratory parameters [eGFR, hemoglobin (Hgb), serum levels of creatinine, uric acid, albumin, proteinuria, hematuria] and also histopathological lesions (Oxford classification parameters, crescents, intensity and pattern of staining for C3, C1Q, IgA, IgG, IgM) as progression markers in patients with IgA Nephropathy (IgAN). Methods: A total of 111 IgAN patients with a follow-up period >1 year or who reached kidney failure [GFR category G5 chronic kidney disease (CKD)] = 50% from the baseline. Kaplan-Meier and Cox proportional hazards analyses were performed. Results: Mean followup period was 33+/-29 months. Thirty-seven (33.3%) patients progressed to kidney failure and 4 (3.6%) patients developed eGFR decline >= 50% from the baseline after a median of 23 and 65 months, respectively. In multivariate Cox regression analysis, baseline levels of Hgb (HR: 0.782, 95% CI 0.559-0.973, p=0.037), serum uric acid (HR: 1.293, 95% CI 1.0231.621, p=0.046), eGFR (HR: 0.966, 95% CI 0.947-0.984, p=0.004) and intensity of C3 staining (HR: 1.550, 95% CI 1.198-1.976, p=0.049) predicted primary endpoint. Serum uric acid level was associated independently with T score (beta=0.303, p=0.005) in patients with eGFR>30 ml/min/m(2). Conclusions: Hyperuricemia and the deposition of C3 are independent risk factors for IgAN progression. (C) 2016 The Author(s) Published by S. Karger AG, Basel
dc.language.isoeng
dc.subjectTemel Bilimler
dc.subjectFİZYOLOJİ
dc.subjectBiyoloji ve Biyokimya
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectPERİFERAL VASKÜLER HASTALIĞI
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectBiyokimya
dc.subjectFizyoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectNefroloji
dc.subjectYaşam Bilimleri
dc.titleThe Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy
dc.typeMakale
dc.relation.journalKIDNEY & BLOOD PRESSURE RESEARCH
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume41
dc.identifier.issue2
dc.identifier.startpage148
dc.identifier.endpage157
dc.contributor.firstauthorID72533


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster